



Scholar Rock to Present at Upcoming Investor Conferences

February 18, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 18, 2026-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences:

- **TD Cowen 46th Annual Health Care Conference:** Scholar Rock is scheduled to participate in a fireside chat at 1:50 p.m. ET on Wednesday, March 4, 2026 in Boston, MA
- **Leerink Partners 2026 Global Healthcare Conference:** Scholar Rock is scheduled to participate in a fireside chat at 2:30 p.m. ET on Tuesday, March 10, 2026 in Miami, FL.
- **Barclays 28th Annual Global Healthcare Conference:** Scholar Rock is scheduled to participate in a fireside chat at 8:30 a.m. ET on Thursday, March 12, 2026 in Miami, FL.

A live webcast of the events will be available under the "Events and Presentations" page within the Investors section of the Scholar Rock website at <http://investors.scholarrock.com>. A replay of the webcasts will be available for approximately 90 days.

About Scholar Rock

Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on X (formerly known as Twitter) or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260218128585/en/): <https://www.businesswire.com/news/home/20260218128585/en/>

Scholar Rock Contacts

Investors

Laura Ekas, Ph.D.

ir@scholarrock.com

917-439-0374

Media

Molly MacLeod, Ph.D.

media@scholarrock.com

802-579-5995

Source: Scholar Rock